Global Imiglucerase Market Growth 2026-2032
Description
The global Imiglucerase market size is predicted to grow from US$ 1081 million in 2025 to US$ 1449 million in 2032; it is expected to grow at a CAGR of 4.4% from 2026 to 2032.
Imiglucerase is a biological agent prepared using recombinant gene technology. It belongs to the category of enzyme replacement therapy drugs, and its core application is in the treatment of the rare disease Gaucher disease. Imiglucerase controls the disease at its metabolic root by artificially supplementing the missing enzyme, and is a core drug for treating type 1 and some types 3 Gaucher disease. Being a recombinant biological agent, it requires long-term intravenous infusion. Although it is relatively expensive, it effectively prevents organ damage and improves patient survival.
Imiglucerase, as a benchmark drug in the field of enzyme replacement therapy for Gaucher disease, is occupying a core position in the global and Chinese rare disease drug market, relying on its clear clinical value and stable demand. In terms of market size, the global and Chinese imiglucerase market had already reached a scale of hundreds of millions of yuan by 2024, and the global market is expected to continue to expand at a steady compound annual growth rate until 2030. This growth trend stems from the increased diagnosis rate of Gaucher disease patients, but even more so from the clinical trust established by the product in long-term treatment.
Currently, the global imiglucerase market is dominated by Sanofi. Through its acquisition of Genzyme, a benchmark company in the global rare disease field, in 2011, Sanofi incorporated imiglucerase (trade name: Cerezo®) into its core product portfolio. The research and development of this product can be traced back to the 1990s—in 1994, imiglucerase was first approved by the US FDA, becoming the first recombinant enzyme replacement therapy drug for the treatment of Gaucher disease, completely changing the predicament of Gaucher disease patients having no effective treatment options. In 2008, Sanofi facilitated the entry of imiglucerase into the Chinese market and obtained approval for its market launch. To date, Sanofi has established an imiglucerase production and supply system covering major global markets, with a sales and service network centered in core cities such as Beijing, Shanghai, and Guangzhou, radiating across the entire country in China alone.
LP Information, Inc. (LPI) ' newest research report, the “Imiglucerase Industry Forecast” looks at past sales and reviews total world Imiglucerase sales in 2025, providing a comprehensive analysis by region and market sector of projected Imiglucerase sales for 2026 through 2032. With Imiglucerase sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Imiglucerase industry.
This Insight Report provides a comprehensive analysis of the global Imiglucerase landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Imiglucerase portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Imiglucerase market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Imiglucerase and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Imiglucerase.
This report presents a comprehensive overview, market shares, and growth opportunities of Imiglucerase market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Type I Gaucher Disease
Type III Gaucher Disease
Segmentation by Application:
Public Hospitals
Private Hospitals
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi (Genzyme)
Generium
ISU Abxis
Key Questions Addressed in this Report
What is the 10-year outlook for the global Imiglucerase market?
What factors are driving Imiglucerase market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Imiglucerase market opportunities vary by end market size?
How does Imiglucerase break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Imiglucerase is a biological agent prepared using recombinant gene technology. It belongs to the category of enzyme replacement therapy drugs, and its core application is in the treatment of the rare disease Gaucher disease. Imiglucerase controls the disease at its metabolic root by artificially supplementing the missing enzyme, and is a core drug for treating type 1 and some types 3 Gaucher disease. Being a recombinant biological agent, it requires long-term intravenous infusion. Although it is relatively expensive, it effectively prevents organ damage and improves patient survival.
Imiglucerase, as a benchmark drug in the field of enzyme replacement therapy for Gaucher disease, is occupying a core position in the global and Chinese rare disease drug market, relying on its clear clinical value and stable demand. In terms of market size, the global and Chinese imiglucerase market had already reached a scale of hundreds of millions of yuan by 2024, and the global market is expected to continue to expand at a steady compound annual growth rate until 2030. This growth trend stems from the increased diagnosis rate of Gaucher disease patients, but even more so from the clinical trust established by the product in long-term treatment.
Currently, the global imiglucerase market is dominated by Sanofi. Through its acquisition of Genzyme, a benchmark company in the global rare disease field, in 2011, Sanofi incorporated imiglucerase (trade name: Cerezo®) into its core product portfolio. The research and development of this product can be traced back to the 1990s—in 1994, imiglucerase was first approved by the US FDA, becoming the first recombinant enzyme replacement therapy drug for the treatment of Gaucher disease, completely changing the predicament of Gaucher disease patients having no effective treatment options. In 2008, Sanofi facilitated the entry of imiglucerase into the Chinese market and obtained approval for its market launch. To date, Sanofi has established an imiglucerase production and supply system covering major global markets, with a sales and service network centered in core cities such as Beijing, Shanghai, and Guangzhou, radiating across the entire country in China alone.
LP Information, Inc. (LPI) ' newest research report, the “Imiglucerase Industry Forecast” looks at past sales and reviews total world Imiglucerase sales in 2025, providing a comprehensive analysis by region and market sector of projected Imiglucerase sales for 2026 through 2032. With Imiglucerase sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Imiglucerase industry.
This Insight Report provides a comprehensive analysis of the global Imiglucerase landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Imiglucerase portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Imiglucerase market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Imiglucerase and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Imiglucerase.
This report presents a comprehensive overview, market shares, and growth opportunities of Imiglucerase market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Type I Gaucher Disease
Type III Gaucher Disease
Segmentation by Application:
Public Hospitals
Private Hospitals
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi (Genzyme)
Generium
ISU Abxis
Key Questions Addressed in this Report
What is the 10-year outlook for the global Imiglucerase market?
What factors are driving Imiglucerase market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Imiglucerase market opportunities vary by end market size?
How does Imiglucerase break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
78 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Imiglucerase by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Imiglucerase by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
